GILD.BA Gilead Sciences, Inc.
Company Analysis
Latest News
🟢 GILD.BA is trading 2% up today on EU approval for Trodelvy and ongoing digestion of HIV pipeline milestones
• Gilead Sciences (GILD.BA) is trading 2% up today at $48540.00. • The European Commission granted marketing authorization for Trodelvy as a first-line...
🔴 Gilead Sciences, Inc. is trading 3.6% down today following FDA acceptance of Yeztugo filing and positive Phase 3 HIV data
Gilead Sciences, Inc. is trading 3.6% down today at $46700.00, following recent announcements of the U.S. FDA's acceptance of its supplemental New Drug...
🟢 Gilead Sciences, Inc. is trading 4.5% up today with no clear catalyst
Gilead Sciences, Inc. is trading 4.5% up at $48620.00 today, as the move appears driven by market volatility rather than specific corporate developments. •...
🟢 Gilead Sciences, Inc. is trading 2.3% up today after FDA accepts sNDA for once-weekly HIV prevention drug
Gilead Sciences, Inc. is trading 2.3% up now at $47,700.00 after U.S. regulators advanced a key HIV prevention program. • The FDA has accepted the...
🟢 Gilead Sciences, Inc. soars 2.4% today after FDA accepts application for once-weekly oral HIV prevention pill
• Gilead Sciences, Inc. is trading 2.4% up at $47,740.00 today, following the U.S. FDA's acceptance of its supplemental New Drug Application (sNDA) for Yeztugo...